Endralazine in patients with severe hypertension and renal insufficiency

Endralazine, a new peripheral vasodilator, was given in conjunction with a beta-blocker to 21 patients with hypertension and chronic renal failure. All subjects were either poorly controlled on their previous antihypertensive regime or were experiencing unacceptable adverse effects from drugs. After 4 weeks blood pressure was reduced in all patients and symptomatic side effects were few. Two patients became anti-nuclear factor (ANF) positive in weak titre but without evidence of the lupus syndrome.